Ultimovacs – executive interview

Ultimovacs – executive interview

Ultimovacs — 7 videos in collection

More on this equity

Ultimovacs is developing novel immunotherapies against cancer. The lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (human telomerase reverse transcriptase), which is expressed in c 85% of all cancer types. UV1 therefore has broad potential in a variety of different settings and combinations.

In this video, CEO Carlos de Sousa and CMO Jens Bjørheim provide an update on the data shared from the legacy Phase I trial, including survival, responses and biomarkers.


You may also be interested in these:

Healthcare

Ultimovacs – executive interview

Ultimovacs

Healthcare

Ultimovacs - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free